Idorsia (OTCPK:IDRS.F) FY Conference March 02, 2026 01:50 PM ET Speaker0All righty. Hi, everyone. Thank you for joining us in the room and online at TD Cowen's 46th Annual Healthcare Conference. I'm Joseph Thome, one of the senior biotech analysts here on the team at TD Cowen. It is my pleasure to have with me today the team from Idorsia, and we have CEO Srishti Gupta, who's gonna give us a brief overview, and then we're gonna dive into some of the programs. Maybe just to kick things off, before we get into ...

Key Takeaways REGN and Sanofi received CHMP support to expand Dupixent for CSU in children aged 2-11 years.Phase III studies showed Dupixent cut itch and hives, and improved disease control at 24 weeks.Dupixent posted $17.8B in 2025 sales for Sanofi, while REGN logged $5.9B in collaboration revenues.Regeneron Pharmaceuticals (REGN) and its partner Sanofi (SNY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recomme ...

The drug and biotech sector has recovered somewhat in 2026 after remaining muted for most of 2025. Drug pricing agreements of Big Pharma with the Trump administration, strong quarterly results, bullish outlook for 2026, robust pipeline activity and a flurry of M&A deals have led to the industry’s recovery. However, it faces its share of headwinds like regular pipeline setbacks, slow ramp-up of newer drugs, patent cliffs, regulatory risks and policy and pricing uncertainty. Despite the headwinds, the industr ...

Core Viewpoint - Moderna's shares increased by approximately 4% following the EMA's CHMP recommendation for marketing authorization of its mRNA-based combination vaccine, mCombriax, targeting COVID-19 and influenza [1][9]. Group 1: Regulatory Approval Process - The CHMP's recommendation will be reviewed by the European Commission, with a final decision anticipated soon [2]. - If approved, mCombriax will be Moderna's fourth marketed product in the EU, following two COVID-19 vaccines and an RSV vaccine [2]. Group 2: Clinical Study Results - The recommendation was supported by data from a pivotal phase III study that met its primary endpoints, showing that a single dose of mCombriax produced higher immune responses against COVID-19 and influenza compared to standalone vaccines [3][9]. - The study involved around 8,000 adults, split into two age cohorts: one for adults aged 65 and older and another for those aged 50 to 64, comparing mCombriax with existing influenza vaccines [4]. Group 3: Stock Performance - Year-to-date, Moderna's stock has surged approximately 82%, significantly outperforming the industry average growth of 10% [7]. Group 4: Product Details and Future Filings - mCombriax combines Moderna's mNexspike and mRNA-1010, an investigational influenza vaccine, with regulatory filings currently under review in multiple regions including the US, Europe, Canada, and Australia [8]. - A final decision by the FDA regarding mCombriax is expected by August 5, 2026 [8]. Group 5: FDA Review and Challenges - Moderna had previously submitted a regulatory filing for mCombriax to the FDA, which was voluntarily withdrawn in May 2025 due to requests for additional efficacy data for the flu component [10]. - The FDA initially refused to review the mRNA-1010 filing but later reversed its decision after Moderna proposed an age-based regulatory pathway for approval [11].

Core Viewpoint - Sanofi's rilzabrutinib has received orphan drug designation in Japan for the treatment of IgG4-related disease, addressing a significant unmet medical need in this rare condition [1][7]. Group 1: Rilzabrutinib's Designation and Clinical Evaluation - The Ministry of Health, Labour and Welfare in Japan granted orphan drug designation to rilzabrutinib for IgG4-RD, highlighting the limited treatment options available for this rare disease [1]. - Rilzabrutinib was evaluated in a phase 2 study, showing a reduction in disease flares and other markers over 52 weeks, while minimizing the need for glucocorticoids [2]. - The safety profile of rilzabrutinib in the phase 2 study was consistent with previous studies, with no new safety signals observed [2]. Group 2: Broader Applications and Regulatory Status - Rilzabrutinib is being studied for multiple rare immune-mediated diseases and received approval for immune thrombocytopenia (ITP) in the US, EU, and UAE in 2025 [3]. - The drug is currently under regulatory review for ITP in Japan and has received expedited designations for various conditions, including IgG4-RD [3]. - Other than the approved ITP indications, the uses of rilzabrutinib for IgG4-RD and other conditions remain investigational [3]. Group 3: Mechanism and Potential Impact - Rilzabrutinib is a novel, oral, reversible covalent BTK inhibitor that aims to restore immune balance through multi-immune modulation [4]. - The drug targets BTK, which plays a critical role in immune-mediated disease processes, indicating its potential effectiveness in treating several rare diseases [4]. - The global prevalence of IgG4-RD is unknown due to its rarity and diagnostic challenges, emphasizing the need for effective treatments like rilzabrutinib [5]. Group 4: Company Overview - Sanofi is an R&D driven biopharma company focused on improving lives through innovative medicines and vaccines, with a commitment to addressing urgent healthcare challenges [6]. - The company is listed on EURONEXT: SAN and NASDAQ: SNY, indicating its presence in major financial markets [6].

投资逻辑： 近期医疗器械领域政策与产业动态密集，创新支持与国际化布局同步推进。国家药监局批准创新医疗器械持续增加， 优先审评目录聚焦脑机接口、高端影像设备等核心领域。同时医保局为手术机器人等相关医疗服务项目建立新的收费 标准，创新产品入院速度有望进一步提升。脑机接口、手术机器人、智能诊断、生物材料等多赛道迎来发展机遇，行 业迈入以临床价值为核心的新发展阶段，国产头部企业将迎来加速发展机遇。 创新药：赛诺菲/再生元的度普利尤单抗获 FDA 批准成为全球首款 AFRS 治疗药物，基于 LIBERTY-AFRS-AIMSIII 期临 床数据，该药在鼻窦混浊评分、鼻息肉缩小及嗅觉改善等关键终点上显著优于安慰剂，安全性与已获批的 CRSwNP 适 应症一致，为这一高复发率疾病提供了首个靶向 2 型炎症的非手术替代方案。 生物制品： 2026 年 2 月 24 日，联邦制药与诺和诺德联合发布 GLP-1/GIP/GCG 三靶点受体激动剂（三激动剂）UBT251 中国 II 期临床研究的主要结果，治疗 24 周后，UBT251 治疗组的平均体重降幅最高达 19.7%（-17.5kg）。全球已有多 款 GLP-1 三靶药物进 ...

新闻发布会现场 智通财经记者 俞凯 图 2月28日上午，上海市政府新闻办举行市政府新闻发布会，介绍2026上海全球投资促进大会暨"投资上海"活动周筹备进展和上海投资促进工作相关 情况。 本届大会主要有四个方面亮点： 一是全景式呈现投资上海的新机遇。本届大会将着力扩大有效投资，优化投资结构，推动投资向科技创新、产业焕新等领域集聚，加快提升现代 化产业体系竞争力。大会将邀请近500家国内外知名企业参加，有戴尔、阿斯利康、GE、赛诺菲、海尔等行业龙头企业，也有博枫资产、KKR、 启明创投等知名投资机构，还有MiniMax、追觅科技、地平线等新锐创新力量。 二是发布赋能新质生产力的新要素。大会将聚焦培育新质生产力，全面展现上海产业生态优势。一是发布一批赋能平台，比如智算资源、语料供 给、企业"走出去"服务等公共平台；智能终端软硬适配、民用飞机先进制造、具身智能零部件等中试平台；以及国地中心人形机器人训练场、高 级别自动驾驶引领区、新型航空器试飞基地等标志性场景，打造前沿硬核的试验场，让好产品不缺应用。二是落地一批重大项目，比如东盛合芯 三维芯片集成制造、通用航空发动机研发生产基地、米其林开放创新中心等，增强产业链韧性 ...

| 企业名称 强生 | 27 97 营业收入(亿美元) 941.93 | | | | --- | --- | --- | --- | | | | 营收同比增减 6% | 研发费用(亿美元) 146. 65 | | 罗氏 | 743.8 | 7% | 158. 12 | | 罗氏 | 743.8 | 7% | 158. 12 | | --- | --- | --- | --- | | 礼来 | 651.79 | 45% | 112 | | 默沙东 | 650. 1 | 1% | 121 | | 辉瑞 | 625. 79 | -2% | 104. 37 | | 阿斯利康 | 587. 39 | 8% | 94. 23 | | 诺华 | 545. 3 | 8% | 120 | | 赛诺菲 | 507.81 | 10% | 102. 54 | | 诺和诺德 | 489 | 6% | 75. 98 | | 葛兰素史克 | 427.94 | 7% | 68. 7 | 近期，强生、罗氏、礼来等多家跨国药企相继披露2025年业绩。其中，强生以942亿美元总营收位居首位，罗氏凭借五大重磅药物获得744.3亿美元收 入，位居第二 ...

Novavax Inc. (NASDAQ:NVAX) shares are down on Friday, possibly on profit-taking after the stock rallied on Thursday following the company's announcement of its fourth-quarter and full-year 2025 financial results. It is worth noting that Novavax has a short interest of 31.41% of its float.Novavax Q4 Profit ShiftNovavax reported a fourth-quarter earnings shift to a profit of 11 cents, compared to a loss of 51 cents a year ago, with revenue hitting $147 million, a 67% increase year-over-year.However, the compa ...

Core Insights - Kymera Therapeutics (KYMR) reported a wider fourth-quarter 2025 loss of 97 cents per share, exceeding the Zacks Consensus Estimate of a loss of 77 cents, and a deterioration from a loss of 88 cents per share in the same quarter last year [1][7] - The company's collaboration revenues were $2.9 million, significantly below the Zacks Consensus Estimate of $30 million, and down from $7.4 million in the year-ago quarter [2][5] - Kymera's shares have increased by 214.2% over the past year, outperforming the industry average rise of 18.6% [2] Financial Performance - Research and development (R&D) expenses rose to $83.8 million, a 16.7% increase year over year, driven by investments in the STAT6 program and other discovery initiatives [3][14] - General and administrative expenses increased by 3.7% year over year to $16.9 million, influenced by higher legal and professional service fees, as well as increased personnel and facility costs [4] - For the full year 2025, revenues decreased by 16.8% to $39.2 million, missing the Zacks Consensus Estimate of $54.7 million, while loss per share increased to $3.69 from $2.98 in 2024 [5] Capital and Funding - In December 2025, Kymera completed an underwritten equity offering that generated approximately $692 million in gross proceeds, raising year-end cash to about $1.6 billion and extending the cash runway into 2029 [4][14] Pipeline Developments - Kymera is advancing its targeted protein degradation (TPD) strategy, with KT-621 in phase 2 development for atopic dermatitis and asthma, showing promising results in recent studies [8][9] - The BROADEN2 phase IIb study for KT-621 has been expanded to include adolescents, with data expected from mid- to late-2027 [10] - KT-579, an oral IRF5 degrader, has begun phase 1 trials following FDA clearance, with results anticipated in the second half of 2026 [11] - The partnered program KT-485/SAR447971 is expected to enter clinical trials in 2026, while preclinical work continues on an oral CDK2 program with Gilead [12][13] Investment Thesis - The investment thesis focuses on the execution of Kymera's pipeline in targeted protein degradation, particularly the progress of KT-621, which could positively impact stock performance [15]